Public warned not to take unapproved weight-loss drug

Public health officials have issued warnings against the use of an unapproved weight-loss drug known as Retatrutide, commonly referred to as “reta.” The drug, which is still in clinical trials by pharmaceutical company Eli Lilly, is being sold and distributed through online channels and social media platforms, despite being illegal to sell in Ireland and other countries. Medical professionals warn that users are experiencing severe side effects, including gastrointestinal distress, organ damage, and hospitalization. According to reports, Retatrutide is increasingly popular among individuals seeking rapid weight loss, particularly within the fitness and bodybuilding communities. Personal trainers and online coaches are advising clients to use the drug, often without disclosing potential risks or offering guidance on managing adverse effects. This lack of oversight has led to serious health complications. Professor Donal O’Shea, a leading obesity consultant, described one case where a patient required hospital treatment due to vomiting and kidney failure following regular injections of Retatrutide. He emphasized that such incidents could become widespread if the drug continues to circulate unchecked. The drug’s side effects include nausea, vomiting, diarrhea, and constipation, along with more severe impacts on the liver, pancreas, and kidneys. Some patients who experience these symptoms fail to disclose their use of Retatrutide, citing embarrassment or fear of judgment. This secrecy complicates medical diagnoses and hinders efforts to address the growing public health concern. One user, Shauna Louise Cleary, an online fitness coach, shared her experience with Retatrutide. She began using the drug in February, intending to prepare for a gym photoshoot in Marbella. Cleary injected the drug twice weekly, hoping to achieve faster results. However, she soon encountered severe side effects, including intense nausea and difficulty standing. Despite reducing her intake, she eventually stopped using the drug after suffering a near collapse during a workout session. Cleary expressed frustration over the physical toll the drug imposed on her body, stating that she did not believe the benefits justified the risk. Eli Lilly has taken action to curb the illegal distribution of Retatrutide, urging social media platforms to prevent the spread of information related to the drug. The company has specifically called on platforms to block content promoting or facilitating the sale of Retatrutide. In response, major platforms such as Meta and TikTok have implemented policies banning advertisements and promotions of weight-loss products, especially those containing false or exaggerated claims. Meta stated it prohibits content that encourages the use of non-medical drugs, while TikTok has removed specific hashtags associated with Retatrutide and continues to monitor and remove violating content. Despite these measures, authorities report that illicit sales persist. The Health Products Regulatory Authority noted a steady increase in the number of social media pages engaged in the unauthorized sale of weight-loss drugs, including Retatrutide. Social media accounts appear to be finding ways to bypass platform restrictions, suggesting that enforcement remains challenging. Professor O’Shea expressed alarm over the situation, noting that the misuse of Retatrutide represents a troubling shift in how weight-loss treatments are accessed and promoted. With his extensive experience in studying GLP-1 medications since 1992, he stressed that the current landscape, where unapproved drugs are being widely circulated via digital channels, is unprecedented and poses significant risks to public health.